Literature DB >> 6319068

Effects of ranitidine and of cimetidine on pentagastrin-stimulated gastric acid secretion.

R H Holloway, B Kuljian, F Eshelman, R W McCallum.   

Abstract

We compared the effect of oral and intravenous ranitidine, a new H2-receptor antagonist, with that of cimetidine on pentagastrin-stimulated gastric acid secretion in normal subjects. Ranitidine in intravenous doses of 20, 60, and 100 mg and oral doses of 100, 150, and 200 mg inhibited acid secretion. Only the 100 mg iv ranitidine dose was substantially more effective than cimetidine. Comparable dose-related decreases in gastric secretory volume were observed. Acid inhibition correlated strongly (r = 0.90) with plasma ranitidine concentration, with the estimated plasma concentration producing 50% inhibition (IC50) being 95 ng/ml. Maximal acid inhibition achieved was 87.3%. We conclude that ranitidine is a potent inhibitor of gastric acid secretion and should be a valuable addition to the medical treatment of acid-peptic disease.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6319068     DOI: 10.1038/clpt.1984.27

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  8 in total

Review 1.  Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations.

Authors:  J H Lin
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Pharmacokinetics of ranitidine in acute upper gastrointestinal haemorrhage.

Authors:  O Varoquaux; J M Trawale; J Doll; J Andrieu; S Grosbuis; M Pays; C Advenier
Journal:  Br J Clin Pharmacol       Date:  1985-12       Impact factor: 4.335

4.  The antisecretory effects of zaltidine, a novel long-acting H2-receptor antagonist, in healthy volunteers and in subjects with a past history of duodenal ulcer.

Authors:  G Laferla; N Buchanan; J Hearns; G P Crean; K E McColl; A T Clucas
Journal:  Br J Clin Pharmacol       Date:  1986-10       Impact factor: 4.335

5.  A long lasting gastrin response to apomorphine revealed by inhibitors of gastric acid secretion.

Authors:  M Goiny; K Brodin; C E Elwin; K Uvnäs-Moberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-07       Impact factor: 3.000

Review 6.  Ranitidine. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer disease and other allied diseases.

Authors:  S M Grant; H D Langtry; R N Brogden
Journal:  Drugs       Date:  1989-06       Impact factor: 9.546

7.  Inhibition of pentagastrin-stimulated gastric acid secretion and plasma levels of the new histamine H2-receptor antagonist ramixotidine dihydrochloride (CM 57755) in human volunteers.

Authors:  A Brassinne; A Dresse; G Basilisco; L Manara
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Pharmacokinetics of ranitidine in critically ill patients.

Authors:  K F Ilett; R L Nation; R Tjokrosetio; W R Thompson; T E Oh; P D Cameron
Journal:  Br J Clin Pharmacol       Date:  1986-03       Impact factor: 4.335

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.